Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP31670 in advanced solid tumors and hematological malignancies
NCT05488548Phase 1Recruiting
- Sponsor
- Epigenetix
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EP31670 in castration-resistant prostate cancer (CRPC), NUT carcinoma (NMC), chronic myelomonocytic leukemia (CMML) and 1 more (3 arms), sponsored by Epigenetix. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Dose Limiting Toxicities at 3 weeks and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
EP31670
03
Conditions
castration-resistant prostate cancer (CRPC)NUT carcinoma (NMC)chronic myelomonocytic leukemia (CMML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05488548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488548.